NHS funding for Saxenda is restricted to specialist tier 3 weight management services under NICE guidance
Notably, the STEP (Semaglutide Treatment Effect in People with obesity) trials, which specifically examined body composition, demonstrated substantial weight loss compared with placebo (NCT03548935) [53], and reductions in fat mass and visceral adipose tissue were accompanied by decreases in lean mass, although the proportion of lean mass relative to total body mass increased (NCT04074161) [54]
I lost 6 pounds the first week, none the second
Taking these medications with other medicines for diabetes, such as insulin or sulfonylureas, may increase the risk of low blood sugar levels
#shifainternationalhospital #antimicrobialstewardship #pharmacy #pharmD #CME #clinicalpharmacy To view or add a comment, sign in Germany has taken a significant step by opening reimbursable Long/Post-COVID off-label use for four medicines